NeoGenomics offers unparalleled services to accelerate your complex drug development program and clinical trials, supported by a network
of College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories.
What makes us different
At NeoGenomics, we understand the needs of pharmaceutical and biotechnology companies, and we align with our partners to support development of therapies that will save lives. With over a decade of experience, we are a trusted partner in oncology research and development, delivering solutions to advance your drug development and clinical trial programs for targeted therapies and emerging treatment modalities.
No matter the scale or business need, we deliver:
- Rapid project initiation with flexible, scalable support for evolving study needs
- Immediate access to experienced MDs, PhDs, and a dedicated project manager, ensuring project integrity
- Available regulatory and quality experts to support our pharma and biotech partners
- Certified pathology staff capable of performing US Food and Drug Administration (FDA)-approved companion diagnostic confirmations
- Seamless end-to-end multi-modal solutions, eliminating the need for multiple vendors
- Broad pharmaceutical test menu and integrated data analysis
- Customized solutions to accelerate your development program
Lab services
Cell therapy solutions
Antibody-drug conjugates (ADCs) solutions
Biomarker solutions
Clinical trials are becoming increasingly complex, with each study presenting unique challenges and nuances. As a rapidly growing oncology-specific clinical research organization (CRO), NeoGenomics partners with biopharma companies to deliver the insights they need. Backed by a dedicated clinical trial team, we ensure that your study objectives are met on time.
NeoGenomics delivers thoughtful oversight to ensure compliance with federal regulations for a successful commercial launch. We provide in-house regulatory and compliance support to our pharma and biotech partners to support their clinical trial requirements, and we have enjoyed a 100% success rate with institutional review board (IRB) and FDA submissions,* often receiving consistent favorable FDA feedback.
More info on regulatory support
*Data on file.
The use of biological signatures to identify patients who are likely to benefit from a particular therapy has greatly accelerated the pace of drug development and approval. Simultaneously, it has complicated drug development by requiring the co-development of a companion diagnostic (CDx) assay to accurately and reproducibly select patients who are likely to benefit from said therapy. We provide specialized scientific expertise to ensure CDx success and accelerate your pipeline progress.
We are pleased to offer complete end-to-end support throughout the commercialization process. NeoGenomics is one of the largest oncology-focused laboratories in the United States, with established relationships with major in vitro diagnostic (IVD) providers, single-site FDA-approved test approvals, and partnerships for ex-US launch needs.
Our commitment to advancing cancer care with real-world multi-modal oncology data solutions makes us a valuable partner to pharmaceutical companies.
Understanding the vital role that data play in precision oncology, NeoGenomics has the scientific expertise and innovation to help pharma companies succeed sooner.
Partner testimonials
Review our variety of publications, poster presentations, and white papers.
Want to learn more about NeoGenomics’ pharma services? Sign up to receive our quarterly newsletter, PharmaConnect.
